← Leaderboards
Bret David Wallace
Symberix, Inc.
$4,364,202
Attributed
$4,364,202
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2018–22$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,364,202 · 6
By mechanism
R44$3,369,356 · 2
R43$994,846 · 4
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Targeted Treatment”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
- Leonard Freedman · Leidos Biomedical Research, Inc.$66,755,704
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
Targeted TreatmentMicrobiomeGut MicrobiomePharmaceutical PreparationsLead CandidateLeadBaseBeta-GlucuronidaseLifeEnzymesIntestinesIn VivoGlucuronidesFutureNovel TherapeuticsSmall MoleculeSide EffectDiarrheaDoseSamplingToxic EffectCost EffectiveIrinotecanMicrobial
Grant awards (9)
Small molecule drugs targeting gut dysbiosis to manage inflammatory bowel disease$304,553
R43 · FY2022 · DK · contact PI
Development of a companion diagnostic to identify patients who respond to microbiome-targeting drugs$846,715
R44 · FY2021 · GM · contact PI
Developing novel inhibitors of the gut microbiome to modulate drug metabolism$787,689
R44 · FY2021 · TR · contact PI
Development of a companion diagnostic to identify patients who respond to microbiome-targeting drugs$884,165
R44 · FY2020 · GM · contact PI
Developing novel inhibitors of the gut microbiome to modulate drug metabolism$625,834
R44 · FY2020 · TR · contact PI
Modulation of gut dysbiosis with Enterobacteriaceae-targeted antiproliferative agents to treat inflammatory bowel disease$231,302
R43 · FY2019 · DK · contact PI
Developing novel inhibitors of the gut microbiome to modulate drug metabolism$224,953
R44 · FY2019 · TR · contact PI
Therapeutic Adjunct to Improve Immunosuppression Outcomes Following Organ Transplantation$238,047
R43 · FY2018 · DK · contact PI
The Benchtop Symbiome: developing an integrated mammalian-microbial assay platform to accelerate microbiome-targeted drug discovery$220,944
R43 · FY2018 · GM · contact PI